Role of Extracellular Vesicles in Hematological Malignancies

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Raimondo, Stefania ^a   Corrado, Chiara ^a   Raimondi, Lavinia ^b   De Leo, Giacomo ^a   Alessandro, Riccardo ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOGENESIS; BIOAVAILABILITY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COMMUNICATION; CELL FUNCTION; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; EXOSOME; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HOST CELL; HUMAN; METASTASIS; NONHUMAN; PROTEOMICS; REVIEW; TARGET CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

EXOSOMES; EXTRACELLULAR VESICLES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOMICS; TUMOR MICROENVIRONMENT;

EID: 84947460139     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/821613     Document Type: Review

References (86)

1. J. Skog, T. Würdinger, S. van Rijn et al., "Glioblastoma microvesicles transport RNAand proteins that promote tumour growth and provide diagnostic biomarkers," Nature Cell Biology, vol. 10, no. 12, pp. 1470-1476, 2008.
2. C. Théry, M. Ostrowski, and E. Segura, "Membrane vesicles as conveyors of immune responses," Nature Reviews Immunology, vol. 9, no. 8, pp. 581-593, 2009.
3. H. F. G. Heijnen, A. E. Schiel, R. Fijnheer, H. J. Geuze, and J. J. Sixma, "Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules," Blood, vol. 94, no. 11, pp. 3791-3799, 1999.
4. G. Raposo, H.W. Nijman, W. Stoorvogel et al., "B lymphocytes secrete antigen-presenting vesicles," Journal of Experimental Medicine, vol. 183, no. 3, pp. 1161-1172, 1996.
5. A. Savina, C. M. Fader, M. T. Damiani, and M. I. Colombo, "Rab11 promotes docking and fusion ofmultivesicular bodies in a calcium-dependent manner," Traffic, vol. 6, no. 2, pp. 131-143, 2005.
6. M. Ostrowski, N. B. Carmo, S. Krumeich et al., "Rab27a and Rab27b control different steps of the exosome secretion pathway," Nature Cell Biology, vol. 12, supplement, pp. 19-30, 2010.
7. C. Hsu, Y. Morohashi, S.-I. Yoshimura et al., "Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C," The Journal of Cell Biology, vol. 189, no. 2, pp. 223-232, 2010.
8. M. F. Baietti, Z. Zhang, E. Mortier et al., "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes," Nature Cell Biology, vol. 14, no. 7, pp. 677-685, 2012.
9. C. Théry, M. Boussac, P. Véron et al., "Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles," Journal of Immunology, vol. 166, no. 12, pp. 7309-7318, 2001.
10. R. Crescitelli, C. Lässer, T. G. Szabó et al., "DistinctRNAprofiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes," Journal of Extracellular Vesicles, vol. 2, 2013.
11. F. Andre, N. E. C. Schartz, M. Movassagh et al., "Malignant effusions and immunogenic tumour-derived exosomes," The Lancet, vol. 360, no. 9329, pp. 295-305, 2002.
12. H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells," Nature Cell Biology, vol. 9, no. 6, pp. 654-659, 2007.
13. A. Clayton, A. Turkes, S. Dewitt, R. Steadman, M. D. Mason, and M. B. Hallett, "Adhesion and signaling by B cell-derived exosomes: the role of integrins," The FASEB Journal, vol. 18, no. 9, pp. 977-979, 2004.
14. A. E. Morelli, A. T. Larregina,W. J. Shufesky et al., "Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells," Blood, vol. 104, no. 10, pp. 3257-3266, 2004.
15. K. Al-Nedawi, B. Meehan, J. Micallef et al., "Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells," Nature Cell Biology, vol. 10, no. 5, pp. 619-624, 2008.
16. Y. Zhang, D. Liu, X. Chen et al., "Secreted monocytic miR-150 enhances targeted endothelial cell migration," Molecular Cell, vol. 39, no. 1, pp. 133-144, 2010.
17. E. Cocucci,G. Racchetti, and J. Meldolesi, "Shedding microvesicles: artefacts no more," Trends in Cell Biology, vol. 19, no. 2, pp. 43-51, 2009.
18. E. Pap,E. Pállinger, M. Pásztoí, and A. Falus, "Highlights of a new type of intercellular communication: microvesicle-based information transfer," Inflammation Research, vol. 58, no. 1, pp. 1-8, 2009.
19. C. Corrado, S. Raimondo, A. Chiesi, F. Ciccia, G. De Leo, and R. Alessandro, "Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications," International Journal ofMolecular Sciences, vol. 14, no. 3, pp. 5338-5366, 2013.
20. M. A. Antonyak, B. Li, L. K. Boroughs et al., "Cancer cellderived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 4852-4857, 2011.
21. H. Peinado, M. Aleckovíc, S. Lavotshkin et al., "Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET," Nature Medicine, vol. 18, no. 6, pp. 883-891, 2012.
22. S. Melo, H. Sugimoto, J. O'Connell et al., "Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis," Cancer Cell, vol. 26, no. 5, pp. 707-721, 2014.
23. J. M. Brown and W. R. Wilson, "Exploiting tumour hypoxia in cancer treatment," Nature Reviews Cancer, vol. 4, no. 6, pp. 437-447, 2004.
24. S.M. Evans,K.D. Judy, I. Dunphy et al., "Hypoxia is important in the biology and aggression of human glial brain tumors," Clinical Cancer Research, vol. 10, no. 24, pp. 8177-8184, 2004.
25. L. S. Ziemer, C. J. Koch, A. Maity, D. P. Magarelli, A. M. Horan, and S. M. Evans, "Hypoxia and VEGF mRNA expression in human tumors," Neoplasia, vol. 3, no. 6, pp. 500-508, 2001.
26. A. B. Scandurro, C. W. Weldon, Y. G. Figueroa, J. Alam, and B. S. Beckman, "Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells," International journal of oncology, vol. 19, no. 1, pp. 129-135, 2001.
27. H. W. King, M. Z. Michael, and J. M. Gleadle, "Hypoxic enhancement of exosome release by breast cancer cells," BMC Cancer, vol. 12, article 421, 2012.
28. C. Salomon, J. Ryan, L. Sobrevia et al., "Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis," PLoS ONE, vol. 8, no. 7,Article ID e68451, 2013.
29. P. Kucharzewska, H. C. Christianson, J. E. Welch et al., "Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 18, pp. 7312-7317, 2013.
30. M. J. Bissell and W. C. Hines, "Why don't we get more cancer A proposed role of the microenvironment in restraining cancer progression," Nature Medicine, vol. 17, no. 3, pp. 320-329, 2011.
31. V. Muralidharan-Chari, J. W. Clancy, A. Sedgwick, and C. D'Souza-Schorey, "Microvesicles: mediators of extracellular communication during cancer progression," Journal of Cell Science, vol. 123, no. 10, pp. 1603-1611, 2010.
32. I. Nazarenko, S. Rana, A. Baumann et al., "Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation," Cancer Research, vol. 70, no. 4, pp. 1668-1678, 2010.
33. J. M. Aliotta, M. Pereira, K. W. Johnson et al., "Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription," ExperimentalHematology, vol. 38,no. 3, pp.233-245,2010.
34. H. Peinado, S. Lavotshkin, and D. Lyden, "The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts," Seminars in Cancer Biology, vol. 21, no. 2, pp. 139-146, 2011.
35. J. Huan, N. Hornick, A. Skinner, N. Goloviznina, C. Roberts, and P. Kurre, "RNA trafficking by acute myelogenous leukemia exosomes," Cancer Research, vol. 73, no. 2, pp. 918-929, 2013.
36. C. Corrado, S. Raimondo, L. Saieva, A. M. Flugy, G. de Leo, and R. Alessandro, "Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells," Cancer Letters, vol. 348, no. 1-2, pp. 71-76, 2014.
37. A. K. Ghosh, C. R. Secreto, T. R. Knox,W. Ding, D. Mukhopadhyay, andN. E. Kay, "Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression," Blood, vol. 115, no. 9, pp. 1755-1764, 2010.
38. J. Cai, Y. Han, H. Ren et al., "Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a novel mechanism for genetic influence between cells," Journal of Molecular Cell Biology, vol. 5, no. 4, pp. 227-238, 2013.
39. J. Cai, G. Wu, X. Tan et al., "Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunodeficient mice," PLoS ONE, vol. 9, no. 8, Article ID e105200, 2014.
40. K. E. de Visser, A. Eichten, and L. M. Coussens, "Paradoxical roles of theimmune systemduring cancer development," Nature Reviews Cancer, vol. 6, no. 1, pp. 24-37, 2006.
41. A. S. Azmi, B. Bao, and F. H. Sarkar, "Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review," Cancer andMetastasis Reviews, vol. 32,no. 3-4, pp. 623-642, 2013.
42. M. Hedlund, O. Nagaeva, D. Kargl, V. Baranov, and L. Mincheva-Nilsson, "Thermal-and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphomaTand B cells," PLoSONE, vol. 6, no. 2, Article ID e16899, 2011.
43. H.-C. Zhang, X.-B. Liu, S. Huang et al., "Microvesicles derived fromhuman umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo," Stem Cells and Development, vol. 21, no. 18, pp. 3289-3297, 2012.
44. A. M. Roccaro, A. Sacco, P. Maiso et al., "BM mesenchymal stromal cell-derived exosomes facilitate multiplemyeloma progression," The Journal of Clinical Investigation, vol. 123, no. 4, pp. 1542-1555, 2013.
45. Y.-T. Ding, S. Kumar, and D.-C. Yu, "The role of endothelial progenitor cells in tumour vasculogenesis," Pathobiology, vol. 75, no. 5, pp. 265-273, 2008.
46. G. Taraboletti, S. D'Ascenzo, I. Giusti et al., "Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH 1," Neoplasia, vol. 8, no. 2, pp. 96-103, 2006.
47. A. Trujillo, C. McGee, and C. R. Cogle, "Angiogenesis in acute myeloid leukemia and opportunities for novel therapies," Journal of Oncology, vol. 2012,Article ID 128608, 9 pages, 2012.
48. N. Giuliani, P. Storti, M. Bolzoni, B. D. Palma, and S. Bonomini, "Angiogenesis and multiple myeloma," Cancer Microenvironment, vol. 4, no. 3, pp. 325-337, 2011.
49. T. Letilovic, R. Vrhovac, S. Verstovsek, B. Jaksic, andA. Ferrajoli, "Role of angiogenesis in chronic lymphocytic leukemia," Cancer, vol. 107, no. 5, pp. 925-934, 2006.
50. C. Marinaccio, B. Nico, E. Maiorano, G. Specchia, and D. Ribatti, "Insights in Hodgkin Lymphoma angiogenesis," Leukemia Research, vol. 38, no. 8, pp. 857-861, 2014.
51. H. F. S. Negaard,N. Iversen, I. M. Bowitz-Lothe et al., "Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors," Leukemia, vol. 23, no. 1, pp. 162-169, 2009.
52. S. Taverna, A. Flugy, L. Saieva et al., "Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis," International Journal of Cancer, vol. 130, no. 9, pp. 2033-2043, 2012.
53. C. Corrado, A. M. Flugy, S. Taverna et al., "Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis," PLoS ONE, vol. 7, no. 8,Article ID e42310, 2012.
54. M. Mineo, S. H. Garfield, S. Taverna et al., "Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion," Angiogenesis, vol. 15, no. 1, pp. 33-45, 2012.
55. J. Wittmann and H.-M. Jäck, "Serum microRNAs as powerful cancer biomarkers," Biochimica et Biophysica Acta-Reviews on Cancer, vol. 1806, no. 2, pp. 200-207, 2010.
56. S. Taverna, V. Amodeo, L. Saieva et al., "Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells," Molecular Cancer, vol. 13, no. 1, article 169, 2014.
57. T. Umezu, K. Ohyashiki, M. Kuroda, and J. H. Ohyashiki, "Leukemia cell to endothelial cell communication via exosomal miRNAs," Oncogene, vol. 32, no. 22, pp. 2747-2755, 2013.
58. H. Tadokoro, T. Umezu, K. Ohyashiki, T. Hirano, and J. H. Ohyashiki, "Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells," The Journal of Biological Chemistry, vol. 288, no. 48, pp. 34343-34351, 2013.
59. J. E. Park, H. S. Tan, A. Datta et al., "Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes," Molecular and Cellular Proteomics, vol. 9, no. 6, pp. 1085-1099, 2010.
60. T. Umezu, H. Tadokoro, K. Azuma, S. Yoshizawa, K. Ohyashiki, and J. H. Ohyashiki, "Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1," Blood, vol. 124, no. 25, pp. 3748-3757, 2014.
61. Y. Liu, X.-J. Zhu, C. Zeng et al., "Microvesicles secreted from human multiple myeloma cells promote angiogenesis," Acta Pharmacologica Sinica, vol. 35, no. 2, pp. 230-238, 2014.
62. J. A. Tickner, A. J. Urquhart, S. A. Stephenson,D. J. Richard, and K. J. O'Byrne, "Functions and therapeutic roles of exosomes in cancer," Frontiers in Oncology, vol. 4, article 127, 2014.
63. M. J. Szczepanski, M. Szajnik, A. Welsh, T. L. Whiteside, and M. Boyiadzis, "Blast-derived microvesicles in sera from patients with acutemyeloid leukemia suppress natural killer cell function viamembrane-associated transforming growth factorbeta1," Haematologica, vol. 96, no. 9, pp. 1302-1309, 2011.
64. F. F. van Doormaal, A. Kleinjan, M. Di Nisio, H. R. Büller, and R. Nieuwland, "Cell-derived microvesicles and cancer," Netherlands Journal of Medicine, vol. 67,no. 7, pp.266-273,2009.
65. D. Zocco, P. Ferruzzi, F. Cappello, W. P. Kuo, and S. Fais, "Extracellular vesicles as shuttles of tumor biomarkers and antitumor drugs," Frontiers in Oncology, vol. 4, article 267, 2014.
66. D. D. Taylor and C. Gercel-Taylor, "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer," Gynecologic Oncology, vol. 110, no. 1, pp. 13-21, 2008.
67. M. Logozzi, A. De Milito, L. Lugini et al., "High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients," PLoS ONE, vol. 4, no. 4,Article ID e5219, 2009.
68. B. K. Thakur, H. Zhang, A. Becker et al., "Double-stranded DNA in exosomes: a novel biomarker in cancer detection," Cell Research, vol. 24, no. 6, pp. 766-769, 2014.
69. K. Mizutani, R. Terazawa, K. Kameyama et al., "Isolation of prostate cancer-related exosomes," Anticancer Research, vol. 34, no. 7, pp. 3419-3423, 2014.
70. R. Cazzoli, F. Buttitta, M. di Nicola et al., "MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer," Journal of Thoracic Oncology, vol. 8, no. 9, pp. 1156-1162, 2013.
71. C.-S. Hong, L. Muller, T. L. Whiteside, and M. Boyiadzis, "Plasma exosomes as markers of therapeutic response in patients with acutemyeloid leukemia," Frontiers in Immunology, vol. 5, article 160, 2014.
72. P. Filipazzi, M. Bürdek, A. Villa, L. Rivoltini, and V. Huber, "Recent advances on the role of tumor exosomes in immunosuppression and disease progression," Seminars in Cancer Biology, vol. 22, no. 4, pp. 342-349, 2012.
73. A. V. Vlassov, S. Magdaleno, R. Setterquist, and R. Conrad, "Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials," Biochimica et Biophysica Acta, vol. 1820, no. 7, pp. 940-948, 2012.
74. A. Ferrajoli, T. D. Shanafelt, C. Ivan et al., "Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia," Blood, vol. 122, no. 11, pp. 1891-1899, 2013.
75. S. Khan, J. R. Aspe, M. G. Asumen et al., "Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential," British Journal of Cancer, vol. 100, no. 7, pp. 1073-1086, 2009.
76. D. Pilzer and Z. Fishelson, "Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis," International Immunology, vol. 17, no. 9, pp. 1239-1248, 2005.
77. D. Pilzer, O. Gasser, O. Moskovich, J. A. Schifferli, and Z. Fishelson, "Emission of membrane vesicles: roles in complement resistance, immunity and cancer," Springer Seminars in Immunopathology, vol. 27, no. 3, pp. 375-387, 2005.
78. R. Safaei, B. J. Larson, T. C. Cheng et al., "Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drugresistant human ovarian carcinoma cells," Molecular Cancer Therapeutics, vol. 4, no. 10, pp. 1595-1604, 2005.
79. J. Yin, X. Yan, X. Yao et al., "Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients," Journal of Cellular and Molecular Medicine, vol. 16, no. 2, pp. 337-348, 2012.
80. J. Wang, A. Hendrix, S. Hernot et al., "Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiplemyeloma cells," Blood, vol. 124, no.4,pp. 555-566, 2014.
81. T. Aung, B. Chapuy, D. Vogel et al., "Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 37, pp. 15336-15341, 2011.
82. B. Chapuy, R. Koch, U. Radunski et al., "Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration," Leukemia, vol. 22, no. 8, pp. 1576-1586, 2008.
83. B. Chapuy, M. Panse, U. Radunski et al., "ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug," Haematologica, vol. 94, no. 11, pp. 1528-1536, 2009.
84. T. Efferth, J.-P. Gillet, A. Sauerbrey et al., "Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia,"Molecular CancerTherapeutics, vol. 5, no. 8, pp. 1986-1994, 2006.
85. P. M. Jones and A. M. George, "The ABC transporter structure and mechanism: perspectives on recent research," Cellular and Molecular Life Sciences, vol. 61, no. 6, pp. 682-699, 2004.
86. C. H. Lee, "Reversing agents for ATP-binding cassette drug transporters," Methods in Molecular Biology, vol. 596, pp. 325-340, 2010.